Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.230
-0.120 (-5.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
Sunshine Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 14.62 | 9.12 | 9.69 | 16.29 | 21.83 | 2.05 |
Short-Term Investments | 0.42 | - | - | - | - | 0.01 |
Cash & Short-Term Investments | 15.04 | 9.12 | 9.69 | 16.29 | 21.83 | 2.05 |
Cash Growth | 61.63% | -5.81% | -40.55% | -25.36% | 963.27% | 105.79% |
Accounts Receivable | 3.89 | 3.46 | 3.87 | 2.55 | 1.91 | 0.01 |
Receivables | 3.89 | 3.46 | 3.87 | 2.55 | 1.91 | 0.01 |
Inventory | 11.66 | 13.47 | 11.28 | 5.73 | 3.29 | 0.11 |
Prepaid Expenses | 0.41 | 0.8 | 1.13 | 0.31 | 0.28 | 0.03 |
Total Current Assets | 31 | 26.85 | 25.97 | 24.89 | 27.31 | 2.2 |
Property, Plant & Equipment | 0.96 | 1.34 | 1.48 | 1.01 | 1.15 | 0.01 |
Other Intangible Assets | 1.89 | 1.89 | 3.02 | 1.44 | 0.78 | - |
Long-Term Deferred Tax Assets | - | - | 0.09 | - | - | - |
Total Assets | 33.86 | 30.08 | 30.56 | 27.35 | 29.24 | 2.2 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.33 | 5.66 | 5.54 | 2.59 | 2.8 | 0.04 |
Accrued Expenses | - | - | - | - | - | 0.05 |
Current Portion of Leases | 0.2 | 0.22 | 0.21 | 0.12 | 0.12 | - |
Current Income Taxes Payable | 0.27 | 0.27 | 0.27 | 0.3 | 0.37 | - |
Other Current Liabilities | - | 0.3 | 0.3 | 2.55 | 3.63 | - |
Total Current Liabilities | 4.79 | 6.44 | 6.31 | 5.55 | 6.93 | 0.09 |
Long-Term Debt | - | - | - | - | - | 1.9 |
Long-Term Leases | 0.43 | 0.6 | 0.74 | 0.54 | 0.64 | - |
Long-Term Deferred Tax Liabilities | - | - | - | 0.05 | 0.04 | - |
Total Liabilities | 5.22 | 7.04 | 7.06 | 6.14 | 7.62 | 1.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0.02 | 0 |
Additional Paid-In Capital | 108.31 | 98.1 | 93.35 | 84.42 | 80.84 | 32.79 |
Retained Earnings | -79.05 | -75.02 | -69.04 | -63.91 | -59.4 | -32.66 |
Comprehensive Income & Other | -0.64 | -0.07 | -0.83 | 0.7 | 0.16 | -0.02 |
Total Common Equity | 28.62 | 23.03 | 23.49 | 21.21 | 21.63 | 0.11 |
Shareholders' Equity | 28.64 | 23.04 | 23.5 | 21.21 | 21.63 | 0.21 |
Total Liabilities & Equity | 33.86 | 30.08 | 30.56 | 27.35 | 29.24 | 2.2 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.63 | 0.81 | 0.95 | 0.66 | 0.77 | 1.9 |
Net Cash (Debt) | 14.41 | 8.31 | 8.73 | 15.63 | 21.06 | 0.15 |
Net Cash Growth | 70.55% | -4.84% | -44.14% | -25.77% | 13687.37% | - |
Net Cash Per Share | 119.63 | 399.85 | - | - | - | - |
Filing Date Shares Outstanding | 0.82 | 0.02 | 0.01 | - | - | - |
Total Common Shares Outstanding | 0.28 | 0.02 | 0.01 | - | - | - |
Working Capital | 26.21 | 20.41 | 19.65 | 19.34 | 20.38 | 2.1 |
Book Value Per Share | 102.85 | 938.67 | 1820.76 | - | - | - |
Tangible Book Value | 26.73 | 21.14 | 20.47 | 19.76 | 20.85 | 0.11 |
Tangible Book Value Per Share | 96.04 | 861.64 | 1586.67 | - | - | - |
Machinery | - | - | 0.79 | 0.54 | 0.48 | - |
Leasehold Improvements | - | - | 0.09 | 0.02 | - | - |